Anti-Tissue Factor Antibodies, Antibody Drug Conjugates, and Related Methods
Antibodies targeting human tissue factor at a unique binding site are developed to address the challenges of excessive TF activity in diseases, providing a selective modulation of TF-dependent processes for therapeutic benefit.
JP7653013B2Active Publication Date: 2025-03-28ICONIC THERAPEUTICS LLC
2 Cites 0 Cited by
Patent Information
- Application Number
- JP2020557125
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-08-02
- Filing Date
- 2019-01-04
- Publication Date
- 2025-03-28
- Estimated Expiration
- 2039-01-04
AI Technical Summary
Technical Problem
Current therapies fail to effectively target tissue factor (TF) in various diseases, including cancer, age-related macular degeneration, and diabetic retinopathy, where TF overexpression contributes to angiogenesis and progression.
Method used
Development of antibodies specifically binding to human tissue factor (TF) at a site distinct from the binding site for factor VIIa, and their use in antibody drug conjugates to modulate TF-dependent signaling.
Benefits of technology
These antibodies selectively inhibit or modulate TF-dependent processes, offering potential therapeutic benefits in diseases characterized by excessive TF activity without interfering with normal coagulation pathways.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs. Also provided herein are methods for making and using the antibodies or ADCs, such as therapeutic and diagnostic methods.
Need to check novelty before this filing date? Find Prior Art